The emerging landscape of neo/adjuvant immunotherapy in renal cell carcinoma
P Dibajnia, LM Cardenas… - Human vaccines & …, 2023 - Taylor & Francis
Adjuvant and neoadjuvant therapies that reduce the risk of renal cell carcinoma (RCC)
recurrence remain an area of unmet need. Advances have been made in metastatic RCC …
recurrence remain an area of unmet need. Advances have been made in metastatic RCC …
Adjuvant therapy for renal cell carcinoma: hype or hope?
F Cosso, G Roviello, G Nesi, S Shabani… - International Journal of …, 2023 - mdpi.com
Renal cell carcinoma (RCC) is the third most common genitourinary cancer accounting for
approximately 180,000 deaths worldwide in 2020. Although over two-thirds of patients …
approximately 180,000 deaths worldwide in 2020. Although over two-thirds of patients …
The role of immune checkpoint inhibitors (ICI) as adjuvant treatment in renal cell carcinoma (RCC): A systematic review and meta-analysis
FSM Monteiro, A Soares, A Rizzo, M Santoni… - Clinical Genitourinary …, 2023 - Elsevier
Pembrolizumab, a PD-1 ICI is approved for the adjuvant treatment of postnephrectomy
patients with clear cell RCC in some countries worldwide. However, recent negative data …
patients with clear cell RCC in some countries worldwide. However, recent negative data …
[HTML][HTML] Cost-effectiveness analysis of pembrolizumab as an adjuvant treatment of renal cell carcinoma post-nephrectomy in the United States
Introduction Pembrolizumab was recently approved as an adjuvant treatment of renal cell
carcinoma (RCC), based on prolonged disease-free survival compared to placebo in the …
carcinoma (RCC), based on prolonged disease-free survival compared to placebo in the …
Predictive performance of prospectively applied ISUP and Fuhrman grade in nonmetastatic renal cell carcinoma
KF Galtung, PM Lauritzen, E Baco, RE Berg… - Anticancer …, 2022 - ar.iiarjournals.org
Background/Aim: In 2012, the International Society of Urological Pathology (ISUP)
recommended replacing Fuhrman with ISUP for grading renal cell carcinoma (RCC). Our …
recommended replacing Fuhrman with ISUP for grading renal cell carcinoma (RCC). Our …
Adjuvante Therapie des Nierenzellkarzinoms
J Bedke, V Grünwald - Die Urologie, 2024 - Springer
Zusammenfassung Der Goldstandard in der Therapie des lokalisierten Nierenzellkarzinoms
(NZK) ist die operative Entfernung des Tumors. Dennoch besteht das Risiko für einen …
(NZK) ist die operative Entfernung des Tumors. Dennoch besteht das Risiko für einen …